🔎 Trials Near Me

Hjem › Burkitts lymfom › Utah

Kliniske studier for Burkitts lymfom i Utah

7 studier for Burkitts lymfom søker deltakere på steder i Utah.

Byer i Utah

Offisiell studietekst (engelsk)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Primary Children's Hospital, Salt Lake City
RekruttererFase 2
366 Days – 46 Years · Alle kjønn · Oppdatert 2. okt. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • Huntsman Cancer Institute/University of Utah, Salt Lake City
RekruttererFase 3
Alder 18 til 39 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT03150693

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

  • Intermountain - Primary Children's Hospital ( Site 1014), Salt Lake City
RekruttererFase 1/2
6 Months – 25 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT06395103

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

  • Primary Children's Hospital, Salt Lake City
RekruttererFase 1
Alder 0 til 18 · Alle kjønn · Oppdatert 16. sep. 2026 · NCT06173518

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Primary Children's Hospital, Salt Lake City
RekruttererFase 2
Alder 1 til 30 · Alle kjønn · Oppdatert 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Primary Children's Hospital, Salt Lake City
RekruttererFase 3
365 Days – 25 Years · Alle kjønn · Oppdatert 25. aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

  • Primary Children's Hospital, Salt Lake City
RekruttererFase 2
Alder 7 til 25 · Alle kjønn · Oppdatert 19. aug. 2026 · NCT05082519

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.